The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
9,295
Sort by:
Arthritis (Musculoskeletal) - Drugs in Development, 2021
US$ 2,000.00
Arthritis (Musculoskeletal) - Drugs in Development, 2021 SUMMARY Arthritis (Musculoskeletal) - Drugs in Development, 2021 provides an overview of the Arthritis pipeline landscape. The report provides...
April 2021
105 pages
Ascites (Gastrointestinal) - Drugs in Development, 2021
US$ 2,000.00
Ascites (Gastrointestinal) - Drugs in Development, 2021 SUMMARY Ascites (Gastrointestinal) - Drugs in Development, 2021 provides an overview of the Ascites pipeline landscape. The report provides comp...
April 2021
30 pages
Astrocytoma (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Astrocytoma (Oncology) - Drugs in Development, 2021 SUMMARY Astrocytoma (Oncology) - Drugs in Development, 2021 provides an overview of the Astrocytoma pipeline landscape. The report provides comprehe...
April 2021
55 pages
B-Cell Leukemia (Oncology) - Drugs in Development, 2021
US$ 2,000.00
B-Cell Leukemia (Oncology) - Drugs in Development, 2021 SUMMARY B-Cell Leukemia (Oncology) - Drugs in Development, 2021 provides an overview of the B-Cell Leukemia pipeline landscape. The report provi...
April 2021
100 pages
B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021
US$ 3,000.00
B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 SUMMARY B Cell Lymphoma 2 (Bcl 2) - Drugs in Development, 2021 provides in depth analysis on B Cell Lymphoma 2 (Bcl 2) targeted pipeline therapeu...
April 2021
50 pages
Beta Tubulin (TUBB) - Drugs in Development, 2021
US$ 3,000.00
Beta Tubulin (TUBB) - Drugs in Development, 2021 SUMMARY Beta Tubulin (TUBB) - Drugs in Development, 2021 provides in depth analysis on Beta Tubulin (TUBB) targeted pipeline therapeutics. The report p...
April 2021
30 pages
Biliary Tumor (Oncology) - Drugs in Development, 2021
US$ 2,000.00
Biliary Tumor (Oncology) - Drugs in Development, 2021 SUMMARY Biliary Tumor (Oncology) - Drugs in Development, 2021 provides an overview of the Biliary Tumor pipeline landscape. The report provides co...
April 2021
45 pages
Blepharospasm (Ophthalmology) - Drugs in Development, 2021
US$ 2,000.00
Blepharospasm (Ophthalmology) - Drugs in Development, 2021 SUMMARY Blepharospasm (Ophthalmology) - Drugs in Development, 2021 provides an overview of the Blepharospasm pipeline landscape. The report p...
April 2021
30 pages
